

Havih, a Maxwell Biosciences Subsidiary, Announces Partnership with the Government of Andhra Pradesh

Category: Business

written by News Mall | December 18, 2025



Havih Envirosciences, an Indian citizen-owned and operated life sciences company and subsidiary of Maxwell Biosciences, announced a strategic partnership with the Government of Andhra Pradesh to establish advanced pharmaceutical research and production capabilities in the state. The collaboration was formalized through an agreement with the Andhra Pradesh Centre for Advanced Research on Livestock Limited (APCARL) on November 21, 2025.



Research and development of novel pharma IP could be a key component for a stronger pharma workforce in India

Under the agreement, APCARL will provide Havih access to advanced R&D laboratories and underground Biosafety Level 4 (BSL-4) biocontainment facilities at its Pulivendula campus in YSR Kadapa district. Havih will develop and supply next-generation anti-infective medicines for early use within Andhra Pradesh, with manufacturing and export centered in India.

“Prime Minister Modi’s *Viksit Bharat @ 2047* vision recognizes that long-term national growth depends on moving up the value chain toward high-margin innovation that creates globally competitive wages for India’s people. India’s economic growth has created momentum; the next phase requires branded pharmaceutical research, advanced IP creation and indigenous scientific leadership.

Havih's partnership with the Government of Andhra Pradesh and APCARL directly advances that vision by building India-owned biocontainment research, first-in-class drug innovation and export-ready pharmaceutical IP. This collaboration is an investment in India's scientists, engineers and future innovators – and a practical step toward India's leadership in global health security," said Scotch McClure, Chairman of Havih Envirosciences.

About Havih Envirosciences

Havih Envirosciences Pvt. Ltd. is an Indian citizen-owned and operated life sciences and environmental health company focused on India-first innovation in advanced anti-infective medicines, biosafety solutions and environmental resilience technologies. Established to build indigenous scientific capability and high-value intellectual property, Havih serves as a platform for translating cutting-edge research into globally competitive products developed and manufactured in India.

Havih's mission is to strengthen India's leadership in branded pharmaceutical research and development by enabling high-margin innovation, advanced containment research and workforce upskilling aligned with national priorities such as *Viksit Bharat @ 2047*, *Make in India* and *Atmanirbhar Bharat*. The company emphasizes biosafety, biodefense and public-health preparedness while supporting international export markets from an India-based innovation core.

Through strategic collaborations with government research institutions and global technology partners, Havih is building a next-generation R&D and production ecosystem designed to deliver durable economic value, globally relevant IP and higher-skilled, higher-wage scientific employment for India's

growing workforce.

About Maxwell Biosciences

Maxwell Biosciences is a global health technology company pioneering a new category of immune-inspired small molecules called Claromers®. Designed to mimic and enhance the body's natural defenses, Claromers® destroy pathogenic bacteria, viruses, fungi and biofilms-without harming healthy cells or the microbiome.

Originally developed for critical infectious diseases, Maxwell's technology is now entering commercial deployment across cosmetics, personal care, medical coatings and biodefense. Claromers® require no refrigeration and are highly stable in even the harshest environments.

Backed by a decade of research, a robust patent portfolio and leadership with deep expertise in science, military, AI and global health, Maxwell has active collaborative agreements with the US military and governments worldwide. FDA clinical trials are planned for 2026. Non-pharmaceutical commercialization is underway, with pilot access for select partners.

Maxwell's AI-first platform enables rapid innovation against the rising threat of resistant pathogens, offering scalable, shelf-stable and microbiome-resilient solutions for a healthier planet.

To learn more about Maxwell Biosciences, visit MaxwellBiosciences.com, or follow us on [X](#) and [LinkedIn](#).

Contacts

Media

press@maxwellbiosciences.com

Investors

investor.relations@maxwellbiosciences.com

